Ameriprise
MACK

Ameriprise’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Ameriprise’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-13,169
Closed -$51K – 3853
2018
Q2 		$51K Buy
13,169
+64
+0.5% +$425 ﹤0.01% 3603
2018
Q1 		$83K Buy
+13,105
New +$108K ﹤0.01% 3568
2016
Q4 		– Sell
-1,375
Closed -$69K – 4003
2016
Q3 		$69K Sell
1,375
-81
-6% -$3.36K ﹤0.01% 3684
2016
Q2 		$62K Buy
1,456
+79
+6% +$4.3K ﹤0.01% 3669
2016
Q1 		$90K Buy
+1,377
New +$71.9K ﹤0.01% 3629
2015
Q4 		– Sell
-34,496
Closed -$2.31M – 3979
2015
Q3 		$2.31M Sell
34,496
-10,679
-24% -$872K ﹤0.01% 2537
2015
Q2 		$4.39M Buy
45,175
+33,116
+275% +$3.15M ﹤0.01% 2234
2015
Q1 		$1.13M Sell
12,059
-4,663
-28% -$397K ﹤0.01% 2880
2014
Q4 		$1.49M Buy
16,722
+986
+6% +$71.8K ﹤0.01% 2683
2014
Q3 		$1.09M Buy
15,736
+15,732
+393,300% +$841K ﹤0.01% 2760
2014
Q2 		$0 Buy
+4
New +$203 ﹤0.01% 5742
2013
Q4 		– Sell
-781
Closed -$23K – 5598
2013
Q3 		$23K Buy
781
+45
+6% +$1.57K ﹤0.01% 4332
2013
Q2 		$39K Buy
+736
New +$32.3K ﹤0.01% 3862

Other funds holding MACK

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Ameriprise's MACK Position: Q3 2018 in Review

Ameriprise sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2018, closing a stake of 13,169 shares — an estimated $51K sold.

Ameriprise first reported a position in MACK in Q2 2013 and held it in 13 quarters. The position peaked at $4.39M in Q2 2015. 63 funds tracked by Wall St. Rank hold MACK as of Q3 2018.

  • Ameriprise reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
  • Ameriprise sold 13,169 Merrimack Pharmaceuticals, Inc. shares in Q3 2018, an estimated $51K.
  • Ameriprise first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 13 quarters.
  • Ameriprise's Merrimack Pharmaceuticals, Inc. position peaked at $4.39M in Q2 2015.
  • 63 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2018.

Based on Ameriprise's 13F filing for Q3 2018, filed 14 Nov 2018.